MX2023011153A - Composicion para obtener la imagen de contraste del cancer. - Google Patents

Composicion para obtener la imagen de contraste del cancer.

Info

Publication number
MX2023011153A
MX2023011153A MX2023011153A MX2023011153A MX2023011153A MX 2023011153 A MX2023011153 A MX 2023011153A MX 2023011153 A MX2023011153 A MX 2023011153A MX 2023011153 A MX2023011153 A MX 2023011153A MX 2023011153 A MX2023011153 A MX 2023011153A
Authority
MX
Mexico
Prior art keywords
contrast imaging
cancer
imaging composition
composition
present
Prior art date
Application number
MX2023011153A
Other languages
English (en)
Inventor
Katsunori Teranishi
Hiroshi Fushiki
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2023011153A publication Critical patent/MX2023011153A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un objeto de la presente invención es proporcionar un agente de contraste capaz de identificar específicamente un tejido con cáncer. Cuando se administra una composición para obtener la imagen de contraste de cáncer que contiene un compuesto de la presente invención, un tejido con cáncer puede ser representado con luz de infrarrojo cercano.
MX2023011153A 2021-03-24 2022-03-23 Composicion para obtener la imagen de contraste del cancer. MX2023011153A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021049967 2021-03-24
PCT/JP2022/013353 WO2022202863A1 (ja) 2021-03-24 2022-03-23 がん造影用組成物

Publications (1)

Publication Number Publication Date
MX2023011153A true MX2023011153A (es) 2023-10-05

Family

ID=83397294

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011153A MX2023011153A (es) 2021-03-24 2022-03-23 Composicion para obtener la imagen de contraste del cancer.

Country Status (10)

Country Link
US (1) US20240181087A1 (es)
EP (1) EP4316529A1 (es)
JP (1) JPWO2022202863A1 (es)
KR (1) KR20230159591A (es)
CN (1) CN117042811A (es)
AU (1) AU2022243280A1 (es)
BR (1) BR112023019364A2 (es)
CA (1) CA3213157A1 (es)
MX (1) MX2023011153A (es)
WO (1) WO2022202863A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005220045A (ja) * 2004-02-04 2005-08-18 Konica Minolta Medical & Graphic Inc 蛍光造影剤
EP2530093B1 (en) * 2010-01-28 2018-11-21 National UniversityCorporation Mie University Indocyanine compound, synthesis method thereof, purification method thereof, diagnostic composition using indocyanine compound, and device for measuring in vivo kinetics and device for visualizing circulation using diagnostic composition
JP2017128532A (ja) * 2016-01-20 2017-07-27 キヤノン株式会社 光学イメージング用造影剤の製造方法、及び光学イメージング用造影剤

Also Published As

Publication number Publication date
CN117042811A (zh) 2023-11-10
BR112023019364A2 (pt) 2023-12-26
US20240181087A1 (en) 2024-06-06
CA3213157A1 (en) 2022-09-29
KR20230159591A (ko) 2023-11-21
AU2022243280A1 (en) 2023-09-28
EP4316529A1 (en) 2024-02-07
WO2022202863A1 (ja) 2022-09-29
JPWO2022202863A1 (es) 2022-09-29

Similar Documents

Publication Publication Date Title
GEP20217281B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
TN2015000391A1 (en) Compounds and compositions for the treatment of parasitic diseases
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
EA201890221A1 (ru) Hbed-бисфосфонаты, их конъюгаты с радиометаллом и их применение в качестве лечебно-диагностических агентов
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
ECSP20021379A (es) Nuevo derivado de fenilpiridina y composición farmacéutica que lo contiene
EA201170997A1 (ru) Производные индола в качестве противораковых агентов
AR117844A1 (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina
MX2023006281A (es) Composicion farmaceutica de agonistas duales de glp-1/glp-2.
EA202092146A1 (ru) Производные пиразотетрагидроизохинолина в качестве положительных модуляторов допаминового d1 рецептора
CL2019001618A1 (es) Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.
MX2023011153A (es) Composicion para obtener la imagen de contraste del cancer.
PE20190452A1 (es) Derivado de triazolopirazinona util como un inhibidor de pde1 humana
CL2023001745A1 (es) Composición farmacéutica de agonistas duales de glp-1/glp-2
CL2023001747A1 (es) Composición farmacéutica de agonistas duales de glp-1/glp-2
BR112018005494A2 (pt) composto, composição farmacêutica, e, método de tratamento de um paciente com uma doença.
BR112022017017A2 (pt) Composição farmacêutica compreendendo composto derivado de benzimidazol
PH12020551620A1 (en) Compositions for preventing or treating dry eye
MX2021004342A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia.